The SELECT trial, which evaluated semaglutide 2.4 mg against placebo for cardiovascular outcomes in patients with overweight and obesity without type 2 diabetes, showed significant decreases in total cholesterol, LDL-C, and triglycerides and an increase in HDL-C at 39.8 months [48]
The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence
Working with SeekPeptides helps identify and address factors limiting response
Policymakers are grappling with whether to mandate coverage or delegate decisions: Legislation: The Treat and Reduce Obesity Act (TROA) was reintroduced in June 2025 in the 119th Congress as S.1973 (Senate) and H.R.4231 (House), led by Sen
[6] [7] Wegovy is prescribed within specialist weight management services according to NICE criteria for adults with obesity or overweight with weight-related comorbidities
Patients with certain genetic profiles may experience faster or slower drug metabolism, meaning some individuals see appetite suppression peak earlier in their injection cycle while others experience gradual, sustained control